IGF2BP2 mRNA and protein are frequently overexpressed across a wide variety of cancer types, as exemplified by proposals for IMP2 expression to be used as a predictive biomarker in prostate cancer as part of a panel of tumor-associated antigens [80]. This evidence concerns the gene IGF2BP2 and Familial prostate cancer.